Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
B.1.1.7
SARS-CoV-2
evolution
genomic epidemiology
genomics
recombination
variants
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
16
06
2021
revised:
29
07
2021
accepted:
11
08
2021
pubmed:
10
9
2021
medline:
14
10
2021
entrez:
9
9
2021
Statut:
ppublish
Résumé
We present evidence for multiple independent origins of recombinant SARS-CoV-2 viruses sampled from late 2020 and early 2021 in the United Kingdom. Their genomes carry single-nucleotide polymorphisms and deletions that are characteristic of the B.1.1.7 variant of concern but lack the full complement of lineage-defining mutations. Instead, the remainder of their genomes share contiguous genetic variation with non-B.1.1.7 viruses circulating in the same geographic area at the same time as the recombinants. In four instances, there was evidence for onward transmission of a recombinant-origin virus, including one transmission cluster of 45 sequenced cases over the course of 2 months. The inferred genomic locations of recombination breakpoints suggest that every community-transmitted recombinant virus inherited its spike region from a B.1.1.7 parental virus, consistent with a transmission advantage for B.1.1.7's set of mutations.
Identifiants
pubmed: 34499854
pii: S0092-8674(21)00984-3
doi: 10.1016/j.cell.2021.08.014
pmc: PMC8367733
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5179-5188.e8Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19027
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/12
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Adv Virus Res. 1997;48:1-100
pubmed: 9233431
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
Genetics. 2007 Jun;176(2):1035-47
pubmed: 17409078
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Mol Biol Evol. 2018 Jan 1;35(1):247-251
pubmed: 29029186
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Nature. 2021 Jan;589(7840):125-130
pubmed: 32906143
Mol Biol Evol. 2018 Feb 1;35(2):518-522
pubmed: 29077904
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Lancet Microbe. 2020 Jul;1(3):e99-e100
pubmed: 32835336
Adv Exp Med Biol. 1995;380:499-506
pubmed: 8830530
Genetics. 2021 Jul 14;218(3):
pubmed: 33983397
J Virol. 1985 Nov;56(2):449-56
pubmed: 2997467
J Virol. 2012 Feb;86(4):2212-20
pubmed: 22114341
Virology. 1991 Nov;185(1):441-5
pubmed: 1656597
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Sci Rep. 2016 Jan 06;6:18825
pubmed: 26732651
Virus Evol. 2021 Jul 15;7(2):veab059
pubmed: 36793768
J Virol. 2014 Oct;88(19):11297-303
pubmed: 25031349
Genetics. 1974 Oct;78(2):737-56
pubmed: 4448362
Nature. 2021 Jul;595(7869):707-712
pubmed: 34098568
Adv Virus Res. 2006;66:193-292
pubmed: 16877062
J Gen Virol. 1999 Oct;80 ( Pt 10):2535-2543
pubmed: 10573145
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
Nat Microbiol. 2020 Nov;5(11):1408-1417
pubmed: 32724171
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
Clin Infect Dis. 2022 Feb 11;74(3):446-454
pubmed: 34013321
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
J Virol. 1988 May;62(5):1810-3
pubmed: 2833625
J Gen Virol. 1974 Apr;23(1):41-9
pubmed: 4364875
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Virus Evol. 2016 Jan 20;2(1):vev023
pubmed: 27774293
J Virol. 2008 Feb;82(4):1819-26
pubmed: 18057240
PLoS One. 2010 May 03;5(5):e10434
pubmed: 20454662
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Mol Biol Evol. 2013 May;30(5):1188-95
pubmed: 23418397